Journal Mobile Options
Table of Contents
Vol. 229, No. 2, 2013
Issue release date: January 2013

Assessment of a Spectral Domain OCT Segmentation Software in a Retrospective Cohort Study of Exudative AMD Patients

Tilleul J. · Querques G. · Canoui-Poitrine F. · Leveziel N. · Souied E.H.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: To assess the ability of the Spectralis optical coherence tomography (OCT) segmentation software to identify the inner limiting membrane and Bruch’s membrane in exudative age-related macular degeneration (AMD) patients. Methods: Thirty-eight eyes of 38 naive exudative AMD patients were retrospectively included. They all had a complete ophthalmologic examination including Spectralis OCT at baseline, at month 1 and 2. Reliability of the segmentation software was assessed by 2 ophthalmologists. Reliability of the segmentation software was defined as good if both inner limiting membrane and Bruch’s membrane were correctly drawn. Results: A total of 38 patients charts were reviewed (114 scans). The inner limiting membrane was correctly drawn by the segmentation software in 114/114 spectral domain OCT scans (100%). Conversely, Bruch’s membrane was correctly drawn in 59/114 scans (51.8%). The software was less reliable in locating Bruch’s membrane in case of pigment epithelium detachment (PED) than without PED (42.5 vs. 73.5%, respectively; p = 0.049), but its reliability was not associated with SRF or CME (p = 0.55 and p = 0.10, respectively). Conclusion: Segmentation of the inner limiting membrane was constantly trustworthy but Bruch’s membrane segmentation was poorly reliable using the automatic Spectralis segmentation software. Based on this software, evaluation of retinal thickness may be incorrect, particularly in case of PED. PED is effectively an important parameter which is not included when measuring retinal thickness.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Huang D, Swanson EA, Lin CP, Schuman JS, Stinson WG, Chang W, Hee MR, Flotte T, Gregory K, Puliafito CA: Optical coherence tomography. Science 1991;254:1178–1181.
  2. Puliafito CA, Hee MR, Lin CP, Reichel E, Schuman JS, Duker JS, Izatt JA, Swanson EA, Fujimoto JG: Imaging of macular diseases with optical coherence tomography. Ophthalmology 1995;102:217–229.
  3. Hee MR, Baumal CR, Puliafito CA, Duker JS, Reichel E, Wilkins JR, Coker JG, Schuman JS, Swanson EA, Fujimoto JG: Optical coherence tomography of age-related macular degeneration and choroidal neovascularization. Ophthalmology 1996;103:1260–1270.
  4. Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, Puliafito CA, Davis JL, Flynn HW Jr, Esquiabro M: An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143:566–583.
  5. Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, Davis JL, Flynn HW Jr, Esquiabro M: A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009;148:43–58.
  6. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY: Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419–1431.
  7. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S: Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432–1444.
  8. Querques G, Azrya S, Martinelli D, Berboucha E, Feldman A, Pece A, Coscas G, Soubrane G, Souied EH: Ranibizumab for exudative age-related macular degeneration: 24-month outcomes from a single-centre institutional setting. Br J Ophthalmol 2010;94:292–296.
  9. Cohen SY, Dubois L, Tadayoni R, Fajnkuchen F, Nghiem-Buffet S, Delahaye-Mazza C, Guiberteau B, Quentel G: Results of one-year’s treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting. Am J Ophthalmol 2009;148:409–413.
  10. Montero JA, Ruiz-Moreno JM, Tavolato M: Follow-up of age-related macular degeneration patients treated by photodynamic therapy with optical coherence tomography 3. Graefes Arch Clin Exp Ophthalmol 2003;241:797–802.
  11. Sadda SR, Wu Z, Walsh AC, Richine L, Dougall J, Cortez R, LaBree LD: Errors in retinal thickness measurements obtained by optical coherence tomography. Ophthalmology 2006;113:285–293.
  12. Costa RA, Calucci D, Skaf M, Cardillo JA, Castro JC, Melo LA Jr, Martins MC, Kaiser PK: Optical coherence tomography. 3. Automatic delineation of the outer neural retinal boundary and its influence on retinal thickness measurements. Invest Ophthalmol Vis Sci 2004;45:2399–2406.
  13. Drexler W, Sattmann H, Hermann B, Ko TH, Stur M, Unterhuber A, Scholda C, Findl O, Wirtitsch M, Fujimoto JG, Fercher AF: Enhanced visualization of macular pathology with the use of ultrahigh-resolution optical coherence tomography. Arch Ophthalmol 2003;121:695–706.
  14. Schmidt-Erfurth U, Leitgeb RA, Michels S, Povazay B, Sacu S, Hermann B, Ahlers C, Sattmann H, Scholda C, Fercher AF, Drexler W: Three-dimensional ultrahigh-resolution optical coherence tomography of macular diseases. Invest Ophthalmol Vis Sci 2005;46:3393–3402.
  15. Srinivasan VJ, Wojtkowski M, Witkin AJ, Duker JS, Ko TH, Carvalho M, Schuman JS, Kowalczyk A, Fujimoto JG: High-definition and 3-dimensional imaging of macular pathologies with high-speed ultrahigh-resolution optical coherence tomography. Ophthalmology 2006;113:2054–2014.
  16. Chen TC, Cense B, Pierce MC, Nassif N, Park BH, Yun SH, White BR, Bouma BE, Tearney GJ, de Boer JF: Spectral domain optical coherence tomography: ultra-high speed, ultra-high resolution ophthalmic imaging. Arch Ophthalmol 2005;123:1715–1720.
  17. Forte R, Cennamo GL, Finelli ML, de Crecchio G: Comparison of time domain Stratus OCT and spectral domain SLO/OCT for assessment of macular thickness and volume. Eye (Lond) 2009;23:2071–2078.
  18. Querques G, Forte R, Berboucha E, Martinelli D, Coscas G, Soubrane G, Souied EH: Spectral-domain versus time domain optical coherence tomography before and after ranibizumab for age-related macular degeneration. Ophthalmic Res 2011;46:152–159.
  19. Coscas G, Coscas F, Zourdani A, Soubrane G: Optical coherence tomography and ARMD (in French). J Fr Ophtalmol 2004;27:3S7–30.
  20. Drexler W, Morgner U, Ghanta RK, Kartner FX, Schuman JS, Fujimoto JG: Ultrahigh-resolution ophthalmic optical coherence tomography. Nat Med 2001;7:502–507.
  21. Krebs I, Falkner-Radler C, Hagen S, Haas P, Brannath W, Lie S, Ansari-Shahrezaei S, Binder S: Quality of the threshold algorithm in age-related macular degeneration: Stratus versus Cirrus OCT. Invest Ophthalmol Vis Sci 2009;50:995–1000.
  22. Querques G, Atmani K, Berboucha E, Martinelli D, Coscas G, Soubrane G, Souied EH: Angiographic analysis of retinal-choroidal anastomosis by confocal scanning laser ophthalmoscopy technology and corresponding (eye-tracked) spectral-domain optical coherence tomography. Retina 2010;30:222–234.
  23. Coscas F, Coscas G, Souied E: Polypoidal choroidal vasculopathy and macroaneurysm: respective roles of scanning laser ophthalmoscopy-indocyanine green angiography and optical coherence tomography. Eur J Ophthalmol 2011;21:331–335.
  24. Horii T, Murakami T, Nishijima K, Sakamoto A, Ota M, Yoshimura N: Optical coherence tomographic characteristics of microaneurysms in diabetic retinopathy. Am J Ophthalmol 2010;150:840–848.
  25. Mylonas G, Ahlers C, Malamos P, Golbaz I, Deak G, Schuetze C, Sacu S, Schmidt-Erfurth U: Comparison of retinal thickness measurements and segmentation performance of four different spectral and time domain OCT devices in neovascular age-related macular degeneration. Br J Ophthalmol 2009;93:1453–1460.
  26. Smretschnig E, Krebs I, Moussa S, Ansari-Shahrezaei S, Binder S: Cirrus OCT versus Spectralis OCT: differences in segmentation in fibrovascular pigment epithelial detachment. Graefes Arch Clin Exp Ophthalmol 2010;248:1693–1698.
  27. Malamos P, Ahlers C, Mylonas G, Schutze C, Deak G, Ritter M, Sacu S, Schmidt-Erfurth U: Evaluation of segmentation procedures using spectral domain optical coherence tomography in exudative age-related macular degeneration. Retina 2011;31:453–463.
  28. Schutze C, Ahlers C, Sacu S, Mylonas G, Sayegh R, Golbaz I, Matt G, Stock G, Schmidt-Erfurth U: Performance of OCT segmentation procedures to assess morphology and extension in geographic atrophy. Acta Ophthalmol 2011;89:235–240.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50